<DOC>
	<DOCNO>NCT01226550</DOCNO>
	<brief_summary>This open , non-randomized , phase I-II , pilot study , evaluate combination optimum cytoreductive surgery hyperthermic intraoperative peritoneal chemotherapy ( HIPEC ) mitomycin C ( MMC ) irinotecan . The latter drug administer escalating dos patient gastric , colorectal , appendicular , primary peritoneal carcinosis ( PC ) .</brief_summary>
	<brief_title>Treatment Primary Peritoneal Carcinosis Digestive Origin Using Cytoreductive Surgery Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C Irinotecan</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Patients peritoneal carcinosis ( PC ) either digestive origin primary : colorectal gastric carcinosis , peritoneal pseudomyxoma mesothelioma , primary carcinosis peritoneum regardless number prior treatment line . A PC primary tumor consider resectable accord preoperative clinical paraclinical data : absence mesenteric retraction absence bladder invasion . Patients good general health ( ASA ≤ 2 ) . Absence cardiorespiratory failure ( PaO2 &gt; 60 mmHg stable condition , dyspnea ≤ NYHA stage 1 , leave ventricular ejection fraction &gt; 60 % . ) . Prothrombin level &gt; 70 % , total bilirubin &lt; 2 x normal level , ASAT ALAT &lt; 2.5 x normal level , alkaline phosphatase &lt; 5 x normal level . Creatinine clearance &gt; 60 ml/min , polynuclear neutrophil &gt; 1500/mm3 , white blood cell count &gt; 4000 /mm3 . Patients give write , informed consent . Patients affiliate French universal healthcare system . Patients PC ovarian , mammary , biliary , pancreatic , bronchial origin . Evolutive patient systemic chemotherapy . Patients PC consider irresectable accord preoperative clinical paraclinical data : mesenteric retraction bladder invasion . Patients poor general health ( ASA &gt; 2 ) . Cardiorespiratory failure ( dyspnea &gt; NYHA stage 1 , PaO2 &lt; 60 mmHg stable condition ) Prothrombin level &lt; 70 % . Any brain abnormality show head scan . Signs heart failure especially leave ventricular ejection fraction &lt; 60 % cardiac ultrasound . Thrombocytopenia &lt; 100 000 / mm3 Visceral metastasis single resectable liver metastasis . Pregnancy breast feed . Chronic inflammatory intestinal disease and/or intestinal obstruction . History severe hypersensitivity irinotecan hydrochloride trihydrate one excipients Campto . Bilirubinemia &gt; 3 time normal upper limit Yellow fever vaccine . Prophylactic treatment phenytoin . Severe medullary insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>hyperthermic intraoperative peritoneal chemotherapy ( HIPEC )</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>peritoneal carcinomatosis ( PC )</keyword>
</DOC>